Interestingly CD8+/PD-1+ T-cells with a gene expression profile comparable to that observed in rodent NASH are also detectable in human NAFLD/NASH livers suggesting the possibility that liver steatosis/steatohepatitis specifically activates CD8+/PD-1+ T-cells in a manner that favours the disease evolution and limits the response to HCC immunotherapy [41] (Figure 1). The gene discussed is PDCD1; the disease is metabolic dysfunction-associated steatotic liver disease.